2. 筋萎縮性側索硬化症 Amyotrophic lateral sclerosis Clinical trials / Disease details
臨床試験数 : 645 / 薬物数 : 589 - (DrugBank : 163) / 標的遺伝子数 : 150 - 標的パスウェイ数 : 225
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05193994 (ClinicalTrials.gov) | February 24, 2022 | 6/12/2021 | Triumeq in Amyotrophic Lateral Sclerosis | Randomised Double-Blind Placebo-Controlled Phase 3 Trial of Triumeq in Amyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis | Drug: Dolutegravir, Abacavir and Lamivudine;Drug: Placebo | Macquarie University, Australia | King's College London;Stichting TRICALS Foundation | Recruiting | 18 Years | N/A | All | 390 | Phase 3 | Australia |